Menu Search
Equities

UNITY Biotechnology Inc

9U90:BER

UNITY Biotechnology Inc

Actions
  • Price (EUR)1.15
  • Today's Change0.044 / 3.99%
  • Shares traded--
  • 1 Year change-38.39%
  • Beta--
Data delayed at least 15 minutes, as of Nov 22 2024 09:50 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Unity Biotechnology, Inc. is a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging. The Company is focused on creating medicines to selectively eliminate or modulate senescent cells and thereby provide transformative benefit in age-related ophthalmologic and neurologic diseases. It is targeting specific biological mechanisms implicated in diseases of aging. Its core therapeutic approach targets cellular senescence and is advancing senolytic programs primarily in ophthalmologic disorders. In addition, it has other programs based on other biologies of aging to include an agonistic antibody to the Tie2 receptor and a Tie2/VEGF bispecific to treat vascular eye disease. UBX1325 is its advanced lead drug candidate for age-related diseases of the eye, including diabetic macular edema. UBX1967 is its back-up compound to UBX1325. UBX2089, an α-Klotho hormone drug candidate, which is being researched for multiple neurology indications.

  • Revenue in USD (TTM)0.00
  • Net income in USD-19.05m
  • Incorporated2009
  • Employees19.00
  • Location
    UNITY Biotechnology Inc285 EAST GRAND AVENUESOUTH SAN FRANCISCO 94080United StatesUSA
  • Phone+1 (650) 416-1192
  • Fax+1 (302) 655-5049
  • Websitehttps://unitybiotechnology.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.